Exact Sciences Corp - EXAS STOCK NEWS

Exact Sciences (EXAS) reported Q4 2024 revenue of $713 million, up 10% year-over-year, with Screening revenue of $553 million (+14%) and Precision Oncology revenue of $161 million (+0.4%). Full-year 2024 revenue reached $2.76 billion, a 10% increase.

The company recorded a Q4 net loss of $865 million ($4.67 per share), primarily due to $838 million in impairment charges related to the Thrive acquisition. Q4 adjusted EBITDA was $75 million, with an 11% margin. Cash position stood at $1.04 billion at quarter-end.

Exact Sciences plans to launch three new cancer tests in 2025: Cologuard Plus™ (Q2), which reduces false positives by 40%, Oncodetect™ (Q2) for molecular residual disease detection, and Cancerguard™ (H2), a multi-cancer screening test showing 62.3% overall sensitivity at 98.5% specificity.

Exact Sciences (Nasdaq: EXAS) has announced it will release its fourth quarter 2024 financial results after U.S. market close on February 19, 2025. The company will host a webcast and conference call at 5 p.m. ET on the same day to discuss the results and business progress.

Interested parties can access the live webcast at www.exactsciences.com. For the conference call, domestic callers should dial 888-330-2384, while international callers can use +1 240-789-2701. The access code for all callers is 4437608. A replay of the webcast will be available on the company's website.

Exact Sciences (NASDAQ: EXAS) revealed clinical validation data for its Oncodetect MRD test at ASCO GI 2025. The Alpha-CORRECT study demonstrated the test's effectiveness in detecting molecular residual disease in colorectal cancer patients, achieving 78% sensitivity post-surgery and 91% during surveillance, with specificities of 80% and 94% respectively.

The Beta-CORRECT study confirmed Oncodetect's prognostic value across stages II, III, and IV colon cancer and rectal cancer. The company plans to launch Oncodetect in Q2 2025 with Medicare coverage. Exact Sciences has established partnerships with NSABP and Flatiron Health to generate additional clinical evidence across multiple solid tumor types, including the CORRECT-I, CORRECT-II, and EXActDNA-003 studies.

Exact Sciences (NASDAQ: EXAS) will present 11 abstracts at the ASCO GI Symposium in January 2025, showcasing significant advances in cancer screening and diagnostics. The company's Oncodetect™ molecular residual disease (MRD) test demonstrated strong performance in Stage III colon cancer patients, with 78% sensitivity post-surgery and 91% during surveillance, along with specificities of 80% and 94% respectively.

The data reveals high adherence rates for the Cologuard® test across different demographic groups: African Americans (62%), Hispanic population (63%), Asian population (69%), and 45-49-year-olds (65%). These rates significantly exceed the generally accepted FIT adherence of 42%. New modeling data indicates that screening with triennial Cologuard results in fewer colorectal cancer cases, lower treatment costs, and higher life years gained compared to blood-based tests at perfect adherence.

Exact Sciences (NASDAQ: EXAS) has announced preliminary Q4 2024 results, expecting total revenue of $713 million, up 10% year-over-year. The company's Screening segment revenue reached $553 million (+14%), while Precision Oncology revenue was $161 million (+0.4%).

For full-year 2024, Exact Sciences anticipates total revenue of $2.76 billion, representing a 10% increase from 2023. The company's Screening revenue grew 13% to $2.104 billion, and Precision Oncology revenue increased 4% to $655 million.

Looking ahead to 2025, the company plans to launch three new cancer tests: Cologuard Plus for colorectal cancer screening, Oncodetect for molecular residual disease, and Cancerguard for multi-cancer screening.

Exact Sciences (Nasdaq: EXAS), a leading cancer screening and diagnostic tests provider, has announced its participation in the upcoming J.P. Morgan Healthcare Conference in San Francisco. The company's management will deliver a presentation followed by a Q&A session on Monday, January 13, 2025, at 1:30 p.m. ET.

Investors and interested parties can access the webcast through the investor relations section of Exact Sciences' website at www.exactsciences.com.

Exact Sciences (Nasdaq: EXAS), a cancer screening and diagnostic tests provider, has announced its management's participation in two upcoming investor conferences in Miami. The company will hold fireside chats at the Citi Global Healthcare Conference on December 3, 2024, at 8:45 a.m. ET, and at the Evercore HealthCONx Conference on December 4, 2024, at 7:30 a.m. ET. Investors can access the webcasts through the investor relations section of Exact Sciences' website.

Exact Sciences (NASDAQ: EXAS) will present 10 abstracts at the 2024 San Antonio Breast Cancer Symposium, showcasing their Precision Oncology portfolio. The presentations focus on the Oncotype DX Breast Recurrence Score® test, highlighting its effectiveness in guiding chemotherapy decisions and managing treatment costs.

New research from Japan demonstrates the test's cost-effectiveness, while other studies reveal that African American women typically show higher Recurrence Score® results compared to non-Hispanic White women, though with similar survival outcomes. The company aims to improve breast cancer care through personalized treatment planning and innovative solutions across all stages of cancer care.

Exact Sciences (NASDAQ: EXAS) presented three abstracts showcasing advancements in multi-cancer early detection (MCED) testing at the AACR Special Conference. A new study demonstrated that their multi-biomarker class approach improved cancer detection sensitivity, showing a 28% increase for stage I cancers and 12.5% for early-stage cancers at 98.5% specificity. New modeling data suggests that adding MCED testing to standard screening could reduce stage IV cancer incidence by 42% and cancer mortality by 17% over 10 years. Analysis from the DETECT-A study indicated MCED testing complements existing lung cancer screening without affecting adherence to standard care.